AACR sits a step earlier in the oncology pipeline than ASCO: basic and translational cancer research rather than clinical trial results, and a more academic-adjacent audience than ASCO's clinical and commercial one. That makes it a sharper GTM signal for research tools and discovery-stage services than for sellers whose buyer is already in late-stage clinical development or manufacturing.
What AACR is
The American Association for Cancer Research Annual Meeting covers basic and translational cancer science: target discovery, mechanism of action, and early-stage research that precedes the clinical trial data presented at ASCO. Attendees are weighted toward academic researchers and biotech discovery teams, and exhibitors follow that audience, research tools, reagents, instrumentation, and discovery-stage service providers rather than the CROs and CDMOs whose buyers sit further along the development pipeline.
The GTM signal at AACR
Exhibiting still reflects a real, budgeted decision to be visible to this specific audience, and remains the strongest company-level signal here, the same as at any show. A named presenter is a specific, timely hook tied to a particular research program. The difference from ASCO is less about how to rank the signals and more about who they point to: AACR activity is a better indicator of an account's discovery-stage research direction than of near-term clinical or commercial readiness. See selling around life science conferences for the general framework.
The outreach window
As with the other flagship shows, exhibitor and speaker information becomes public ahead of the meeting, giving a lead-time window to identify which accounts are presenting or exhibiting and plan outreach before the show opens. Given AACR's research-heavy audience, pre-show outreach that references a specific research program or presented abstract tends to land better than a general company-level pitch. The post-show window holds for a few weeks before a reference to the meeting stops reading as current.
Who this matters most for
A research tools or reagents vendor selling into discovery-stage oncology labs will find AACR one of the tighter-fit shows on the calendar. A CRO with early discovery or translational-services capability can still use it to spot emerging programs before they reach the clinical stage tracked at ASCO, though it is a secondary show for most clinical-stage CRO pipelines. A CDMO generally gets less direct value here than at a manufacturing-focused show, since AACR skews earlier than most CDMO buying decisions.